Human insulin like growth factor, animal free, pure and liquid stable, Short™ AE-IGF-1

Supplier: CELLRX LTD

8000 8010 8005 8011 8013
CELX8000EA 0 EUR
CELX8000 CELX8010 CELX8005 CELX8011 CELX8013
Human insulin like growth factor, animal free, pure and liquid stable, Short™ AE-IGF-1
Proteins and Peptides

Short™ AE-IGF-1 is a recombinant protein of human insulin-like growth factor-I (IGF-1) that has been engineered with an N-terminal Ala-Glu sequence, enabling higher specific activity versus IGF-1 over a longer time course in small to large-scale culture systems and bioreactors. It is approximately 100-fold more biologically potent, in-vitro, than insulin and significantly increases recombinant protein production while reducing apoptosis. Short™ AE-IGF-1 is produced and tested under ISO 9001, ISO 14001, ISO 45001 accreditation, fully defined animal-free components. It is liquid stable, high purity with requisite performance at a compelling price.


  • Higher effective concentration throughout the fermentation by reducing the binding of IGF-1 binding proteins present in cell culture
  • Increases refolding efficiency
  • Facilitates high-yield expression and recovery of the target protein
  • Significantly reduces the cost of upstream manufacturing processes
  • ShortTM AE-IGF-1 has no requirement for reconstitution, carrier proteins, excipients, stabilisers or aliquoting to smaller volumes
  • Eliminating the need for bulk powder mixing or risk of influencing cell culture pH and osmolality
  • Reduction in handling and therefore variability
  • 4-year, liquid stable, shelf life at 2 to 8 °C
  • ISO 45001, ISO 9001, ISO 14001 compliant production using a fully defined animal-free component process
  • Two-year forecast demand maintained in secure storage


Short™ AE-IGF-1 is manufactured by CellRx using a proprietary Escherichia coli-based expression system. The process utilises fully defined animal-free components, proprietary feed and induction methods within a high cell density (HCD), fed-batch, bioreactor system. The recombinant IGF molecule accumulates as inclusion bodies which are subsequently recovered, solubilised and refolded into a stable tertiary structure and purified using various downstream unit operations, yielding ≥95% RP-HPLC and ≥97% SDS-PAGE pure molecule that is highly bioactive. Each batch is supplied with a detailed certificate of analysis (CoA) and BSE/TSE free compliancy statement.


Certifikace: Produced under ISO 9001, ISO 14001, ISO 45001 accreditation, each batch has the associated CoA and TSE/BSE free compliancy statement.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR